Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Research: GLP-1 Medication Users Reduce Spending on Groceries and Dining Out - Featured image
Health

Research: GLP-1 Medication Users Reduce Spending on Groceries and Dining Out

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·December 26, 2025·2 min read

On this page

  • GLP-1 Users Reduce Spending on Groceries and Dining Out
  • Decreased Grocery Spending
  • Shifting Spending Habits

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

A recent study published in the Journal of Marketing Research indicates that families using GLP-1 medications are reducing their spending on food. The research examined purchasing habits and revealed a correlation between GLP-1 use and decreased spending on groceries and dining out.

Share

On this page

  • GLP-1 Users Reduce Spending on Groceries and Dining Out
  • Decreased Grocery Spending
  • Shifting Spending Habits

GLP-1 Users Reduce Spending on Groceries and Dining Out

According to a study featured in the Journal of Marketing Research on December 18, families using GLP-1 medications are allocating less money to food, encompassing both grocery stores and restaurants.

GLP-1 drugs, such as Ozempic, Wegovy, and Mounjaro, function by regulating blood sugar levels, suppressing appetite, and facilitating weight loss. It's estimated that 1 in 8 adults currently use a GLP-1 medication.

The study, which analyzed data from 150,000 households, demonstrated a clear connection between the use of GLP-1 medications and changes in a family's purchasing behavior.

Decreased Grocery Spending

Within six months of a family member starting a GLP-1 medication, grocery store expenditures decreased by 5.3%. Notably, higher-income households experienced an even more significant reduction of 8.2%. Health tracking apps like Shotlee can help monitor dietary changes during this period.

Purchasing preferences also shifted, with a 10.1% decline in snack purchases, along with similar decreases for sweets, baked goods, and cookies. Sales of bread, meat, and eggs also experienced a decline.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

Conversely, spending on yogurt, fresh fruit, nutrition bars, and meat snacks saw an increase.

Shifting Spending Habits

According to assistant professor Sylvia Hristakeva, a co-author of the study, the primary trend is a decrease in overall food purchases. She further noted that spending habits become ingrained once consumers establish them. Even when some users discontinue GLP-1 use, these spending patterns persist, making them harder to differentiate from pre-adoption spending habits.

The research extended beyond grocery shopping, revealing that spending at fast-food establishments, coffee shops, and other limited-service eateries decreased by approximately 8%.

However, about one-third of the participants discontinued GLP-1 use during the study and reverted to their prior habits. According to the study's authors, "Their grocery baskets became slightly less healthy than before they started, driven in part by increased spending on categories such as candy and chocolate."

Source Information

Originally published by PEOPLE.com.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds
Health & Wellness

Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds

A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.

7 min read
Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation
Health & Wellness

Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation

The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.

7 min read
Beyond Weight Loss: The Next Wave of GLP-1 Drugs
Health & Wellness

Beyond Weight Loss: The Next Wave of GLP-1 Drugs

The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.

7 min read

Same topic: Weight Loss

All Weight Loss articles →
Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise
Medical News

Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise

Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.

7 min read
Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym
Medical Insights

Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym

For individuals struggling with difficult-to-control type 2 diabetes and weight management, even powerful GLP-1 medications might not be enough. New research highlights the significant role of hypercortisolism and the promising potential of Korlym in optimizing treatment outcomes.

6 min read
Beyond the Needle: New Oral Semaglutide Tech Could Change Weight Loss Forever
Medical Innovation

Beyond the Needle: New Oral Semaglutide Tech Could Change Weight Loss Forever

Duke University researchers have developed a novel oral delivery system for GLP-1 medications that protects peptides from stomach acid, potentially eliminating the need for injections.

8 min read

More in Health

Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?
Health & Wellness

Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?

Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.

7 min read
Ozempic & Wegovy's Shadow: The Rise of Gray Market Peptides
Health & Wellness

Ozempic & Wegovy's Shadow: The Rise of Gray Market Peptides

The surge in popularity of GLP-1 medications like Ozempic and Wegovy has inadvertently fueled a growing 'gray market' for peptides. This unregulated trade, often facilitated by cryptocurrency, presents significant risks to consumers seeking cheaper alternatives or unapproved compounds.

6 min read
Share this article
  1. Home
  2. Blog
  3. Research: GLP-1 Medication Users Reduce Spending on Groceries and Dining Out
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community